Abbott Laboratories (ABL) Price & Analysis
ABL Stock Chart & Stats
- Day’s Range
- EUR 93.80 - EUR 95.44
- 52-Week Range
- EUR 70.10 - EUR 113.36
- Previous Close
- EUR 93.08
- Volume
- 1,012
- Average Volume (3M)
- 628
- Market Cap
- EUR 163.99B
- Enterprise Value
- EUR 185.82B
- Total Cash (Recent Filing)
- EUR 5.60B
- Total Debt (Recent Filing)
- EUR 32.61B
- Price to Earnings (P/E)
- 39.3
- Beta
- 0.30
- Next Earnings
- Jan 27, 2027
- EPS Estimate
- 1.46
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.29%
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare Portfolio
Abbott’s presence across four healthcare segments diversifies revenue sources and reduces reliance on any single product category. Recurring demand for diagnostics consumables, diabetes sensors, nutrition products, and medicines supports a broad, durable operating base over the next several quarters.
Strong Cash Generation
Robust and growing free cash flow gives Abbott substantial capacity to fund research, product launches, dividends, debt management, and selective acquisitions. Free cash flow also tracks earnings closely, indicating that reported profitability is converting into usable cash for strategic investment.
Innovation And Growth Pipeline
Elevated R&D investment and a broad pipeline provide multiple avenues for future product-led growth across devices, diagnostics, and pharmaceuticals. Recent approvals and launches, including Libre Duo and electrophysiology products, demonstrate continued commercialization capability and portfolio renewal.
Bears Say
Higher Leverage
The sharp increase in debt reduces financial flexibility relative to prior periods and makes Abbott more dependent on sustained operating cash generation. Higher leverage can constrain capital allocation and increase sensitivity to refinancing costs or weaker operating conditions over the medium term.
Margin Compression
Recent margin deterioration indicates that earnings growth is not converting as efficiently as it did in 2025. If normalization or higher costs persist, lower profitability could limit internal funding for innovation and reduce the benefit of Abbott’s otherwise steady revenue expansion.
Diabetes Pricing And Reimbursement Pressure
Slower diabetes growth affects an important innovation-driven business and reflects both pricing pressure abroad and limited reimbursement access for a broader type 2 population. These constraints could temper sensor volume growth and reduce the near-term payoff from Abbott’s diabetes pipeline.
ABL FAQ
What was Abbott Laboratories’s price range in the past 12 months?
What is Abbott Laboratories’s market cap?
When is Abbott Laboratories’s upcoming earnings report date?
How were Abbott Laboratories’s earnings last quarter?
Is Abbott Laboratories overvalued?
Does Abbott Laboratories pay dividends?
What is Abbott Laboratories’s EPS estimate?
How many shares outstanding does Abbott Laboratories have?
What happened to Abbott Laboratories’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Abbott Laboratories?
What is the TipRanks Smart Score and how is it calculated?
Abbott Laboratories Stock Smart Score
Company Description
Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford
- Employees
- 115,000
- Website
- www.abbott.com
- Address
- 100 Abbott Park Road, Abbott Park, IL, 60064-6400, US
Abbott Laboratories (ABL) Earnings & Revenues
ABL Earnings Call
Earnings Call SentimentPositive
The call was strongly constructive: Abbott delivered 7% sales growth, 9% EPS growth, margin expansion, broad segment growth, multiple product approvals and launches, and announced a strategic nutrition separation intended to improve the growth and margin profile of the remaining company. The main negatives were a reduced full-year revenue outlook, short-term electrophysiology and diabetes headwinds, cybersecurity-related disruption in cancer diagnostics, foreign-exchange pressure, and uncertainty around 2027 guidance and CMS reimbursement timing. Highlights significantly outweighed the lowlights.
View all DE:ABL earnings summariesABL Net sales Breakdown
- 12.49% Established Pharmaceutical Products
- 19.06% Nutritional Products
- 20.16% Diagnostic Products
- 48.25% Medical Devices
- 0.04% Other
ABL Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 5 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 12 | 0 | 0 |